[144] Medpace Holdings, Inc. SEC Filing

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) filed a Form 144 reporting a proposed sale of 1,662 common shares. The shares are held at Fidelity Brokerage Services and are scheduled for an approximate sale date of 08/19/2025 on the NASDAQ. The aggregate market value is reported as $772,893.91 and the total number of common shares outstanding is 28,093,026, meaning the shares represent approximately 0.0059% of outstanding stock. The shares were acquired on 02/08/2024 by a stock option exercise from the issuer, paid in cash on the acquisition date. The filer reports no securities sold in the past three months for the account.

Positive

• Clear provenance: Shares were acquired by stock option exercise and paid for in cash on 02/08/2024
• Full disclosure: Broker, number of shares, aggregate market value, approximate sale date, and outstanding shares are provided
• Low market impact: Proposed sale equals approximately 0.0059% of outstanding shares

Negative

• No material negatives disclosed: The filing contains routine sale information and no adverse items are reported

Insights

Financial Analyst

TL;DR: Routine insider sale disclosure; small volume relative to outstanding shares, no recent prior sales reported.

The filing is a standard Rule 144 notice showing an insider or affiliated person intends to sell 1,662 shares valued at $772,893.91 on NASDAQ via Fidelity. The shares were acquired by option exercise and paid for in cash on 02/08/2024. The sale size is immaterial relative to the 28,093,026 shares outstanding (about 0.0059%). The absence of reported sales in the past three months indicates this is not part of recent clustered dispositions. From a market-impact perspective this disclosure is routine and likely non-material.

Corporate Governance Expert

TL;DR: Compliance-focused filing demonstrates adherence to Rule 144 requirements; no red flags visible in the notice.

The Form 144 supplies required information: acquisition method (stock option exercise), acquisition and payment date (02/08/2024), broker details (Fidelity Brokerage Services LLC), and anticipated sale date (08/19/2025). The filer affirms no material non-public information is known. Given the small percentage of outstanding shares and the clear provenance of the shares, this appears to be a standard, compliant disclosure rather than a governance concern.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1662	772893.91	28093026	08/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/08/2024	Stock Option Exercise	Issuer			1662	02/08/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Medpace's (MEDP) Form 144 report?

The Form 144 reports a proposed sale of 1,662 common shares held at Fidelity with an aggregate market value of $772,893.91 and an approximate sale date of 08/19/2025.

How were the Medpace shares acquired?

The shares were acquired on 02/08/2024 through a stock option exercise from the issuer, with payment made in cash on the same date.

What percentage of Medpace's outstanding shares does the sale represent?

The filing reports 28,093,026 shares outstanding; 1,662 shares represent approximately 0.0059% of the outstanding common stock.

Did the filer sell any Medpace securities in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months for the account.

Where will the Medpace shares be sold?

The shares are listed to be sold via Fidelity Brokerage Services LLC on the NASDAQ exchange.